-
Triterpene Prodrug for Targeted OSCC Chemotherapy
2026-08-27
This 2024 ACS Applied Materials & Interfaces study developed a carrier-free, self-assembled prodrug from glycyrrhetinic acid and ginsenoside Rh2 for oral squamous cell carcinoma. Its central innovation is a thioketal-linked ROS-responsive design in which glycyrrhetinic acid helps amplify oxidative stress, promoting further drug release and synergistic tumor-cell apoptosis.
-
Neuromedin S (rat): Practical GPCR Assay Guide
2026-08-27
Neuromedin S (rat), SKU B5466, provides a defined peptide input for controlled neuromedin U receptor signaling and GPCR/G protein signaling experiments. It is suitable for research assay development and rat-focused pathway studies, but should not be used to infer potency, therapeutic activity, diagnostic performance, or cross-species validity when directly matched paper evidence is unavailable.
-
Ribociclib, Acid Reduction, and pH-Mediated Absorption
2026-08-26
Desai and colleagues combined an Analytical Quality by Design framework with a biorelevant micro-dissolution model to examine whether physiological pH shifts could alter ribociclib succinate solubility in the presence of acid-reducing therapy. Although solubility decreased after gastric and intestinal pH transitions, the authors concluded that the changes were unlikely to produce a clinically meaningful absorption interaction, while emphasizing the value of this workflow for early formulation and drug-interaction risk assessment.
-
Honokiol N1672 for Reliable Cell Assays
2026-08-26
Learn how Honokiol (SKU N1672) can help researchers separate cytostasis from cell death, control solvent and stability variables, and interpret viability data more rigorously. This scenario-based guide combines product specifications with evidence on in vitro drug-response measurement.
-
SLC25A1, Senescence, and Cisplatin Resistance in HNSCC
2026-08-25
The reference study identifies SLC25A1 as a regulator of cisplatin resistance in head and neck squamous cell carcinoma, linking mitochondrial citrate transport to H3K27ac-dependent transcription and cellular senescence. Its findings position SLC25A1 as both a candidate biomarker and a therapeutic target, while also emphasizing the need to interpret β-galactosidase readouts within a broader senescence assay framework.
-
CIH, Gut Microbiota, and Mitochondrial Apoptosis
2026-08-25
This 2026 study connects chronic intermittent hypoxia with lung apoptosis through coordinated changes in gut microbiota, fatty-acid metabolism, and mitochondrial fission. Its combined microbiome, metabolomics, histological, and pharmacological design suggests that DRP1-dependent mitochondrial injury is a mechanistic node linking intestinal and pulmonary responses to CIH.
-
SGI-1027 DNA Methyltransferase Inhibitor Workflows
2026-08-24
SGI-1027 is a DNA methyltransferase inhibitor for connecting DNMT activity, promoter methylation, tumor suppressor gene reactivation, and cancer-cell response in one experimental design. Its strongest use-case is not a single viability endpoint, but a layered workflow that separates growth arrest from cell death while confirming epigenetic mechanism.
-
Intravesical p21 mRNA–LNP Therapy for Bladder Cancer
2026-08-24
This 2026 FASEB Journal study developed chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21 expression, disrupted tumor-cell proliferation, and suppressed orthotopic tumor growth while producing predominantly bladder-localized protein expression in mice.
-
Angiotensin II: Redox Logic in Vascular Assays
2026-08-23
Angiotensin II is more than a vasoconstrictor: it is a controllable probe of receptor-driven redox signaling, VEGF induction, and vascular remodeling. This guide translates the LOX-1–dependent angiogenesis study into practical assay decisions for mechanistic vascular research.
-
(+)-Bicuculline Protocol and QC Guide
2026-08-22
(+)-Bicuculline is a research reagent for controlled blockade of GABAA-mediated inhibitory signaling, with applications in synaptic physiology and neuronal signaling assays. This guide covers solubility, storage, controls, and troubleshooting; the compound is for scientific research only and must not be used for diagnosis, treatment, or clinical decision-making.
-
Cholesterol in mRNA-LNP Workflows
2026-08-22
Learn how to use Cholesterol as a controlled formulation variable for lipid nanoparticle, membrane, and lipid metabolism experiments. This practical guide connects cholesterol handling and assay design with localized p21 mRNA-LNP delivery research while clearly separating published findings from workflow recommendations.
-
MRT68921: Rethinking ULK1 Control in Autophagy
2026-08-21
A thought-leadership guide to using MRT68921 as a mechanistic ULK1/2 perturbation tool, with emphasis on AMPK–ULK1 biology, ATG13 phosphorylation blockade, LC3 flux measurement, experimental controls, translational maturity, and study design limitations.
-
CDELNs Relieve Sertoli-Cell Cycle Arrest
2026-08-20
This reference study identifies Cistanche deserticola exosome-like nanovesicles (CDELNs) as a plant-derived intervention for cyclophosphamide-induced testicular injury. Its central mechanistic finding is that CDELN-delivered miR159b-3p targets P21, promotes CDK1 activation, and alleviates cell-cycle arrest in Sertoli cells, with human single-cell transcriptomic data providing translational context.
-
PGE2 Workflows for Inflammation Research
2026-08-20
Build reproducible Prostaglandin E2 assays for receptor pharmacology, inflammatory cell models, and biomaterial screening. This practical guide connects PGE2 exposure design with the stimulus-responsive hydrogel strategy reported for intervertebral disc degeneration.
-
15-PGDH Inhibition Supports Muscle Repair During Weight Loss
2026-08-19
A 2026 PNAS study identifies 15-PGDH inhibition as a way to improve muscle stem cell activity, regenerated myofiber growth, and force recovery during semaglutide-associated weight loss in obese mice. The findings suggest that combining a GLP-1 receptor agonist with a 15-PGDH inhibitor may improve postinjury muscle quality without eliminating the desired reduction in body weight.